News Hub | News Direct

Majority of medical and nursing students planning careers outside patient care as fears of burnout and staff shortages leave them worried about the future

Elsevier

Elsevier Health’s first global “Clinician of the Future 2023: Education Edition” highlights students’ deep concerns about balancing their commitment to patient care with their own well-being. The report also identifies key insights into students’ excitement and fears towards technology and AI in healthcare education Today, Elsevier Health, a global leader in evidence-based clinical practice content, research publishing and information analytics, releases its Clinician of the Future 2023: Education Edition, providing unparalleled insights into the experiences of medical and nursing students and the consequences for the NHS and educators in the UK. The report reveals how the challenges of being a frontline health professional today are impacting the longer-term career decisions of students, highlighting increasingly challenging times ahead for an already overburdened healthcare system. Although almost 9 out of 10 medical and nursing students in the UK feel devoted to improving patients’ lives, findings reveal that 58% already see their current studies as a steppingstone towards a broader career in healthcare that will not involve directly caring for patients. The Clinician of the Future 2023: Education Edition presents a worrying snapshot of the pressures that medical and nursing students feel today alongside the impending alarm they have for life in clinical practice: 20% of medical and nursing students in the UK are considering quitting their undergraduate studies 57% of medical and nursing students in the UK report they are worried about their mental well-being 64% of medical and nursing students in the UK believe they will suffer from clinician burnout 75% of medical and nursing students in the UK are concerned about healthcare staff shortages and the impact this would have on them in their future role Anjola Awe, a third-year medical student at King’s College London, said: “I have always known that I wanted to be a doctor; I’ve dedicated my life to getting to this stage. Honestly, the findings and themes in the report are not at all surprising to me or my peers; we know only too well the reality of what being a frontline healthcare professional means today. We need to be vocal about the pressure we are under, the state of our mental health, and the volume of our academic workload.” As of June this year, there were more than 125,000 vacancies in secondary care in England, and over 10% of all nursing posts remain unfilled. 1 Despite the NHS treating more patients than before the pandemic, the waiting list for NHS treatment currently stands at a record 7.75 million. 2 Against this backdrop, it is unsurprising that medical and nursing students in the UK are concerned about the challenges they will face in the future. Dr Philip Xiu, a general practitioner and educational lead who supports medical students and junior doctors in Leeds, West Yorkshire, said: “As an educator, I see daily how vital it is we address students’ well-being concerns. Doubling enrolment won’t resolve looming workforce shortages if issues impeding student wellness go unresolved. We must equip them with critical thinking to aid sound clinical decisions, and partnership skills to involve patients meaningfully in care. By listening and responding to students’ needs, we can graduate resilient, empowered clinicians ready to elevate healthcare.” The Clinician of the Future 2023: Education Edition also identifies key insights into both the excitement and reservation towards technology and generative AI student curriculum. In the UK, 53% of medical and nursing students say they are excited at the potential of AI; however, 54% report they are worried about its use to support education. Furthermore, 74% admit to feeling overwhelmed by the amount of information they are expected to retain, with 44% now using generative AI, such as ChatGPT and Bard. Jan Herzhoff, President of Elsevier Health, said: “It’s clear that healthcare across the globe is facing unprecedented pressures, and that the next generation of medical and nursing students are anxious about their future. Whether through the use of technology or engaging learning resources, we must support students with new and innovative approaches to enable them to achieve their potential. However, the issues raised in this report can’t be tackled in isolation; it is essential that the whole healthcare community comes together to ensure a sustainable pipeline of healthcare professionals.” The Clinician of the Future 2023: Education Edition is the third edition published as part of Elsevier Health’s Clinician of the Future program, serving as the global health ecosystem’s leading pulse on the changes and challenges facing the doctors and nurses of today and tomorrow. For the full Clinician of the Future 2023: Education Edition, which includes robust data on global student attitudes toward health education, the future of healthcare, as well as the perspectives of instructors and more, click here. ### References: The British Medical Association. NHS medical staffing data analysis, The British Medical Association. Available at: https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/workforce/nhs-medical-staffing-data-analysis (Accessed: 18 October 2023). The British Medical Association. NHS backlog data analysis, The British Medical Association. Available at: https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/pressures/nhs-backlog-data-analysis (Accessed: 18 October 2023). Notes to editors: Research Methodology The Clinician of the Future 2023: Education Edition presents the results of a global survey of 2,212 students and two roundtable sessions with key opinion leaders in faculty in the US and UK. The aim is to gain a deep understanding of students’ experiences today and their expectations of the future in healthcare, as well as the perspectives of those instructing them. Elsevier Health’s commitments In addition to the Clinician of the Future 2023: Education Edition, we are committed to the following: Community Advisor Programmes of Osmosis: Providing elements of mentorship and connection to clinician communities Campus visits and feedback from students: Listening and learning through student feedback on how they are approaching their education challenges Year of the Zebra: An initiative to increase awareness of rare diseases and the benefits of patient care Hackathons: Providing clinical challenges for students in North America to advance their clinical education. Hosting webinars on resilience and depression in healthcare, as well as developing podcast episodes relevant to healthcare challenges Continued internships for medical and nursing students Supporting scholarships for minority students through the Elsevier Foundation About Elsevier Health For more than 140 years, Elsevier has supported the work of researchers and healthcare professionals by providing current, evidence-based information, that can help empower students and clinicians to provide the best healthcare possible. Growing from our roots, Elsevier Health applies innovation, facilitates insights, and helps drive more informed decision-making for our customers across global health. We support health providers by providing accessible, trusted evidence-based information to take on the infodemic; prepare more future health professionals with effective tools and resources; provide insights that help clinicians improve patient outcomes; deliver healthcare that is truly inclusive; and supports a more personalized and localized healthcare experience. Diversity and inclusion are the foundation of our innovation, and our teams are committed to creating education and practice solutions that reflect the diversity of our world. Elsevier is helping lay the groundwork for more equitable healthcare worldwide; We bring the same rigor to our digital information solutions as we do to our publishing, allowing us to offer knowledge and valuable analytics that help our users make breakthroughs and drive progress for the benefit of every patient. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses. Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet and Cell; 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details Dan DiPietro-James Global Media Relations Director dan.james@elsevier.com Chris West Senior Manager, Global Communications c.west1@elsevier.com Company Website https://www.elsevier.com/

October 30, 2023 03:45 AM Eastern Daylight Time

Visit by His Majesty’s Trade Commissioner for North America to Electric Works, Fort Wayne, Indiana

Ancora L&G

Ancora L&G, yesterday welcomed Emma Wade-Smith OBE to Electric Works, in her capacity as His Majesty’s Trade Commissioner for North America and HM Consul General New York, during an official visit to Indiana. During the visit, the Trade Commissioner also met with representatives from the Indiana Economic Development Corporation, the City of Fort Wayne, NEI, and Greater Fort Wayne Inc., as well as regional business leaders. Electric Works, the former site of the General Electric campus, was developed by a public-private partnership of Ancora, Biggs Group, and Weigand Construction, together with the City of Fort Wayne, Allen County, and the State of Indiana. Construction started in 2020, with a strategic focus on urban redevelopment and a commitment to community revitalization. At its peak, the site on which Electric Works stands—an 18-building industrial complex—employed about a third of Fort Wayne's workforce and for over eight decades, produced electric motors, transformers and other critical components. Following decades of deindustrialization and waves of job cuts, the campus closed in 2015. The West Campus – Phase 1 – of Electric Works is a $286 million mixed-use development of 740,000 sq. ft.; the largest historic adaptive reuse project in the State of Indiana. West Campus includes a mix of uses including creative office, retail, entertainment, healthcare, innovation and co-working, a public market and local produce food hall, education, as well as public and event spaces. Building on the success of the West Campus, Phase 2 of Electric Works is planned as a $143.4 million mixed-use development of market rate housing, affordable and low-income housing - including units targeted to 55+ age bracket; over 10,000 sq. ft. new model early childhood learning center in partnership with a university to train new teachers; commercial space; a health/wellness center and parking. As part of the visit, there was a tour of Amp Lab, a new public education model for up to 400 11th and 12th grade students, which provides a STEAM (Science Technology Engineering Arts and Mathematics) curriculum and immersive learning and internship opportunities, in partnership with Electric Works’ businesses. Amp Lab has supported 800 pupils so far from the Fort Wayne area. Jeff Kingsbury, Chief Connectivity Officer, Ancora L&G, said, “To achieve inclusive growth, innovation districts like Electric Works prioritize talent attraction, development, and retention. Affordable housing and education are important to talent, and are therefore critical economic development issues in both the U.S. and the U.K. We discussed these shared challenges and opportunities with the Trade Commissioner during her visit to the campus and appreciate the time she spent with us and her interest and support for the community’s vision of Electric Works.” Emma Wade Smith OBE, HM Trade Commissioner for North America and HM Consul General New York, said: “ We signed the UK’s first State-level trade and economic cooperation agreement with Indiana in May 2022. At the heart of our ambitions is increasing trade and spurring more inclusive and sustainable economic growth, where opportunities and meaningful jobs are accessible to people across our communities. The Ancora Electric Works development is a terrific example of how UK-US collaboration can enable the revitalisation of such iconic and historic industrial sites. The transformation of this facility has captured the imagination of the community, by promoting access to opportunities that support our shared priorities in innovation, STEAM (science, technology, engineering, arts and math) and sustainability.” Riley Johnson, Director of Amp Lab, said, “Amp Lab is a unique learning environment built for students of diverse backgrounds to gain real-world experience. We were honored to host Trade Commissioner Emma Wade-Smith and thrilled to be recognized as a model of innovative and agile education.” ENDS Notes to editors Ancora L&G A joint venture between U.S.-based science and technology real estate developer Ancora and Legal & General Capital ( LGC ), the investment arm of global asset manager Legal & General, Ancora L&G acquires and develops real estate to serve high-growth science, technology, and innovation tenants in partnership with and proximate to leading U.S. anchor institutions. Ancora was founded in 2019 by Josh Parker with co-founders John Philipchuck and Jeff Kingsbury. Currently capitalized at $500 million with plans to expand to $4 billion, Ancora L&G currently has projects in Atlanta, Georgia (Georgia Tech); Providence, Rhode Island (Brown University); and New Haven, Connecticut (Yale University). Legal & General Capital Legal & General Capital (LGC) is Legal & General Group’s alternative asset platform, creating assets for Legal & General Retirement and third-party clients in order to achieve improved risk-adjusted returns for our shareholders. LGC has built its market leading capabilities in a range of alternative assets, delivering depth of resource, track record and intellectual property. Investing in the real economy and creating alternative assets that deliver a tangible societal impact, its purpose is to invest society’s capital for society’s benefit. L&G has invested around £30 billion ($37 million) in levelling-up regional UK economies and has strong track record in investing in technology and life sciences. LGC’s investments include residential property; specialist commercial real estate; clean energy; alternative credit; and venture capital. As LGC’s capability to create alternative assets continues to grow, it will not only continue to grow its balance sheet of alternative assets but also create alternative assets for third party investors. Legal & General Group Established in 1836, Legal & General is one of the UK’s leading financial services groups and a major global investor, with international businesses in the U.S., Europe, Middle East, and Asia. With over £1.24 trillion in total assets under management, we are the UK’s largest investment manager for corporate pension plans and a UK market leader in pension risk transfer, life insurance, workplace pensions and retirement income. Legal & General Group currently manages $1.4 trillion of assets globally and is increasing its presence in the U.S. for both equity and debt vehicles. The year-old Ancora L&G joint venture builds on the successful track record of Ancora’s team and the investing record of LGC in the UK, including over $5 billion currently committed to science and technology development projects at Oxford, Manchester, and other leading universities in the UK. Contact Details Meir Kahtan Public Relations, LLC (MKPR) Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Director of External Engagement, Legal & General Margrit Williams +1 347-387-7555 margrit.williams@landg.com

October 27, 2023 04:52 PM Eastern Daylight Time

Image

Hainan Boao Hope City Pioneering Unique Medical Policies and Driving Collaboration with Denmark's Biopharmaceutical Industry

Hainan Boao Lecheng International Medical Tourism Pilot Zone

HAINAN, CHINA - Media OutReach - 28 October 2023 - From 12 to 13 October, a delegation from Hainan Province, organised by the Hainan Provincial Government, visited Denmark for a series business events to attract investment and talents. During the events, the first and currently the only special medical zone in China, the Boao Lecheng International Medical Tourism Pilot Zone（Boao Hope City） was featured at the Hainan Free Trade Port Lecheng Denmark Promotion Conference, the delegation also took the opportunity to visit some local pharmaceutical companies and relevant institutions in Denmark, sharing opportunities and showcasing the aspirations to achieve win-win cooperation. Representatives and officials from over 30 renowned international pharmaceutical and medical device companies, such as ALK from Denmark, the Nordic Life Science Partners ApS (NLSP), and the Danish Life Science Cluster, gathered to explore potential collaborations and shared goals in the medical sector between Denmark and the Hainan Free Trade Port at the Promotion Event. The discussions primarily focused on the emerging opportunities and future prospects for cooperation, as well as the specific areas of collaboration within the biopharmaceutical industry. Fruitful conversations were held with the Hainan delegation, fostering meaningful exchanges. The upcoming 2 nd Boao International Conference on Real World Studies of Medical Products, scheduled for the end of October this year, also captured the interest of the attendees. It is estimated that approximately 800 experts, scholars, and executives from domestic and international pharmaceutical regulatory agencies, research institutes, and pharmaceutical companies will participate in the conference. During the event, the Boao Lecheng International Medical Tourism Pilot Zone Administration, the Danish Life Science Cluster, and NLSP came together to sign a strategic cooperation agreement. The agreement aims to foster deeper collaboration in various areas such as healthcare, chronic disease prevention and management, telemedicine, digital health, as well as the introduction of innovative drugs and medical devices. On the following day, the Boao Lecheng International Medical Tourism Pilot Zone Administration, along with representatives from medical institutions in the zone, continued their investment and business activities in Denmark. They actively engaged in exchanges and established connections with Healthcare Denmark, ALK, and other innovative pharmaceutical companies and relevant institutions in Denmark, with the aim of advancing cooperation in the biopharmaceutical industry. Officials from the Hainan Provincial Government acknowledged Denmark's global reputation in the healthcare sector and highlighted the open environment for foreign trade and unique medical policies offered by the Hainan Free Trade Port that could bring benefits to the Boao Hope City. As the benefits and advantages provided by the policies of the Hainan Free Trade Port are gradually becoming evident and accessible and the business environment improves, both Denmark and Hainan can capitalise on their respective strengths to explore substantial opportunities for cooperation in the medical sector. Representatives from Healthcare Denmark acknowledged the thriving development of the Hainan Free Trade Port, which presents multinational pharmaceutical companies with extensive growth prospects. They expressed their dedication to focusing on Hainan and the Boao Hope City, making the most of the distinctive policy benefits and strategic location offered by the Hainan Free Trade Port and the Boao Hope City. They also emphasised their intention to leverage their institutional connections to high-quality medical resources in Denmark to foster deeper cooperation and explore opportunities for development. Hainan the Boao Hope City（ http://en.lecityhn.com/ ） has capitalised on the benefits of the "pilot zone" policy and the collaboration with international pharmaceutical and medical device companies. It has forged strong partnerships with more than 170 companies in the pharmaceutical and medical device sectors from over 20 countries and regions. This collaborative effort has facilitated the introduction of over 350 urgently needed imported medical devices for clinical use. Additionally, leveraging the Boao Hope City's real-world evidence-based clinical evaluation, twelve products have successfully obtained registration in the domestic market. As a result, the Boao Hope City has emerged as the primary gateway for international innovative pharmaceutical and medical devices to expedite their entry into the Chinese market. Moving forward, the Boao Hope City will further enhance its commitment to openness and cooperation. It will strengthen collaborations with global pharmaceutical companies and exceptional expert teams, constantly introducing high-quality medical resources and advanced pharmaceuticals into the technologies from around the world. The aim is to expedite the entry of international innovative Chinese market, ultimately benefiting the general public. These efforts will also contribute to positioning the Hainan Free Trade Port as a leading hub for medical innovation in China. Contact Details Chen Xi +86 898 6283 0087 chenxi@lecityhn.com

October 27, 2023 01:58 PM Eastern Daylight Time

Video Image

James McDevitt, Head of Equity Sales & Trading at Roberts & Ryan, Inc., is selected by Irish America Magazine for its 26th Annual Wall Street 50

Roberts & Ryan, Inc.

Roberts & Ryan, Inc., America’s first Service-Disabled Veteran-Owned Broker Dealer, is proud to recognize James McDevitt for his selection to Irish America Magazine’s 26th Annual Wall Street 50. The magazine’s Wall Street 50 recognizes the outstanding accomplishments and success of the best and the brightest Irish American and Irish-born leaders of the financial industry. Mr. McDevitt will be honored at the magazine’s gala dinner on Monday, October 30, 2023, at The New York Yacht Club. Jim’s Irish heritage can be traced back to both sets of Grandparents who emigrated to the United States in the late 1920’s. The McDevitt side from County Derry, and the maternal side from County Clare. Ireland and all things Irish have always been highlighted at family events, the history, and the luck that found the family in NYC. Mr. McDevitt is head of Equities Sales & Trading, Capital Markets at Roberts & Ryan, Inc., with an expertise in equity trading. He is a graduate of Oneota State College in New York, where he received his Bachelor of Arts degree, with a focus on American History. He also studied Technical Analysis at the New York Institute of Finance. Jim was a specialist on the floor of the New York Stock Exchange (NYSE) for 25 years, rising to become a partner at MJ Meehan & Co, and then as a Senior Vice President with Bank of America Specialists. During his career, Jim managed the trading post for marquee NYSE listed securities including Citibank, Walmart, Colgate, Sprint, McDonald’s, and JP Morgan. Jim spent three years at Academy Securities as a Managing Director selling fixed income and equity services to Corporate Treasurers. Jim has been involved in a number of charities and is a Board Member of Roberts & Ryan, Inc. He resides in Long Branch, NJ with his wife Nancy. They have three children, Patrick, Jennifer, and Colin. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker dealer providing services in debt and equity capital markets, equity and fixed-income secondary trading, as well as corporate access events. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations since 2018, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of veterans and their families, focusing on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

October 27, 2023 09:00 AM Eastern Daylight Time

News Release

Zynex makes Healthcare Technology Report’s Top 100 healthcare tech companies for 2nd straight year

Zynex Medical

Zynex Inc Founder and CEO Thomas Sandgaard joined Steve Darling from Proactive to share news the company has been recognized as one of the Top 100 Healthcare Technology Companies of 2023 by The Healthcare Technology Report. Zynex secured the 23rd spot on the list, marking its second consecutive appearance in the top 100. Sandgaard says this is the second year in a row that Zynex has received recognition in The Healthcare Technology Report's top 100 list. In the previous year, the company was ranked 33rd. Zynex's consistent presence on this prestigious list underscores its ongoing commitment to innovation and excellence in healthcare technology. The company has a focus on pain management and hospital monitoring products. While both divisions are important, the company's primary revenue source lies in pain management, where they've maintained a successful business model for 27 years. Their pain management therapies are side-effect-free and covered by insurance companies, leading to impressive annual revenues, expected to exceed $200 million in the near future. The profitability of the pain management division enables Zynex to fund the development of products in the monitoring division. This financial strength and product diversity attract various types of investors, both retail and institutional. Zynex's recent financial performance has been outstanding, with consistent growth and successful quarterly results, continually surpassing analyst estimates. Zynex's future growth primarily hinges on its pain management division, with significant revenue expected in the coming years. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 26, 2023 02:33 PM Eastern Daylight Time

Video

News Release

Ondine Biomedical’s Steriwave nasal photodisinfection platform now used across Canada

Ondine Biomedical Inc

Ondine Biomedical Inc president and chief technology officer Nicolas Loebel joined Steve Darling from Proactive to share news the company’s Steriwave technology is being implemented at the Queen Elizabeth II Health Sciences Centre in Halifax which is a significant development for infection prevention in orthopedic surgery. The Queen Elizabeth II Health Sciences Centre in Halifax, affiliated with Dalhousie University, has adopted Steriwave, Ondine Biomedical's infection prevention method, for use in orthopedic surgeries. This technology is designed to reduce the risk of post-surgical infections, a critical concern in healthcare settings. The company's research highlights its ability to combat extensively drug-resistant microbes (XDR), an alarming threat to patient safety. Ondine's platform effectively kills these microbes, creating a barrier against antimicrobial resistance. The implementation of Steriwave is particularly crucial as healthcare institutions worldwide grapple with concerns about antimicrobial resistance. The rise of drug-resistant pathogens poses a significant threat, making infection prevention and control paramount in hospitals. Steriwave is now available in hospitals across Canada, including renowned institutions like Vancouver General Hospital, the University of British Columbia, Ottawa hospitals, and the Montreal Heart Institute. This widespread adoption highlights the technology's effectiveness and the growing recognition of its role in reducing healthcare-associated infections. The statistics related to healthcare-associated infections in Canada are concerning. One in nine hospital patients in Canada experiences a healthcare-associated infection, resulting in approximately 12,000 deaths annually. Antibiotic-resistant infections contribute significantly to this mortality rate. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 26, 2023 10:31 AM Eastern Daylight Time

Video

Kate Hudson Joins Symbiome as Creative Advisor

Symbiome

Symbiome ™, the pioneering microbiome research & development skincare brand announced today that actress and entrepreneur Kate Hudson joined the company as a Creative Advisor. As an avid Symbiome customer, Hudson will join Symbiome’s team of scientists and executives as they develop the next generation of microbiome products in consumer verticals ranging from skin to gut and oral health. Symbiome addresses the root causes of inflammatory disease in global populations, with a core mission to restore health by studying the ancestral human microbiome. With health as the primary design parameter for consumer product development, Symbiome’s eponymous skincare business is the first result of over five years of advanced microbiome research. "Kate and I are both passionate about the importance of the microbiome to our health and well-being,” says Larry Weiss, natural products chemist, Stanford-trained MD, and the CEO and Founder of Symbiome. “We are committed to developing scientifically validated products with the highest standards that help people understand and unlock the potential of the microbiome to improve their health. I am thrilled to welcome Kate to the Symbiome team” “Almost immediately after I started using Symbiome skincare, I could see and feel the difference,” says award-winning actress and entrepreneur Kate Hudson. “I am proud and excited to join the brilliant and dedicated Symbiome team on their mission to improve health from the outside in. I look forward to a future where the products that we love also nourish our microbiome, enhancing our beauty and our health.” About Symbiome. Weiss Bioscience, Inc. is a San Francisco-based microbiome biotechnology company focusing on health and wellness and the developer of the Symbiome ® brand of BioIntact ® fermented skincare products. Weiss Bioscience has sponsored three international academic research expeditions deep into the Amazon rainforest, defining an evolutionary reference point for the human microbiome and transforming our understanding of the healthy microbiome. Symbiome scientists have translated this groundbreaking research into a unique line of proprietary skincare products formulated with naturally fermented Amazonian botanicals to restore what has been lost in the modern world. Symbiome’s skincare lineup includes ten clean, organic, sustainable, and traceable products, all with less than eight ingredients. Learn more about Symbiome, and follow Symbiome on Instagram, LinkedIn, and Facebook. Contact Details BPCM Archita Patel +1 281-725-2121 archita@bpcm.com Company Website https://www.symbiome.com

October 25, 2023 12:00 PM Eastern Daylight Time

Centre for Neuro Skills’ Dr. Mark Ashley to Present at American Congress of Rehabilitation Medicine Centennial Conference

Centre for Neuro Skills

Dr. Mark J. Ashley, CEO and Founder of Centre for Neuro Skills (CNS), will be a featured presenter and course speaker at the American Congress of Rehabilitation Medicine’s (ACRM) 100 th Annual Conference, the world’s largest interdisciplinary rehabilitation research event, in Atlanta, GA, from October 30 through November 2. The conference will open with the ACRM Leadership Development Course, a one-day workshop providing tools for effective mentorship and leadership. With more than 40 years of clinical and business leadership experience, Dr. Ashley will present a unique approach to mentoring and offer strategic planning tools for healthcare professionals. As one of four selected plenary presenters, Dr. Ashley will also open day two of the conference with his presentation, “The History, Efficacy, and Potential of Post-Acute Community-Based Rehabilitation for Acquired Brain Injury,” which analyzes the origins and evolution of community-based rehabilitation and explores the potential for this level of treatment. “Every year, about 1.5 million Americans experience a traumatic brain injury,” said Dr. Ashley. “It’s crucial that we continue researching and advancing brain injury rehabilitation and treatment to improve patient care and outcomes. I’m honored to participate in ACRM’s annual conference, collaborating with other rehabilitation providers to promote research that will benefit patients.” *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

October 25, 2023 08:01 AM Pacific Daylight Time

Image

xCures Partners with the Pancreatic Cancer Action Network (PanCAN)

xCures

xCures, a leader in real-time clinical data technology, is thrilled to announce a pivotal partnership with the Pancreatic Cancer Action Network (PanCAN). As part of the agreement, PanCAN's researchers and grantees will have unparalleled access to xCures' deidentified Real-time, Regulatory-grade Clinical data. This collaboration aims to drive innovations and breakthroughs in pancreatic cancer research by harnessing the power of real-time patient data. xCures database boasts fully longitudinal clinical data from thousands of pancreatic cancer patients, including over 25,000 locations and ~4,000 medical records per patient. The benefits of this partnership extend beyond the research community. xCures is making its xINFORM patient portal available to PanCAN's leading Patient Services program. The state-of-the-art portal aggregates and centralizes patients’ medical records and structures them into a computable format and an easy-to-understand longitudinal timeline. The xINFORM portal supports patients in being matched with suitable treatments and clinical programs, obtaining invaluable second opinions. Sudheer Doss, Ph.D., Chief Business Officer of PanCAN, shared his enthusiasm for the partnership: "We're always in search of innovative ways to serve our patient community better and accelerate pancreatic cancer research. As part of the comprehensive free services we offer through our PanCAN Patient Services program, this platform can pave the way for identifying optimal treatments and ensuring that our patients receive the best care possible." The PanCAN-xCures partnership blends the strengths of both organizations to advance patient outcomes and bolster research capabilities. “We at xCures are deeply committed to placing patients at the forefront of all our endeavors,” said Mika Newton, CEO of xCures. “This new partnership with PanCan is a testament to our dedication to advancing patient-centric solutions and strengthening our bond with patient advocacy organizations. Together, we will usher in a brighter, more hopeful future for all.” About xCures xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, up-to-date care summary that helps cancer patients get the right therapy at the right time. The platform's portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com. About PanCAN The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive. For 18 years in a row, PanCAN has earned a Four-Star Rating from Charity Navigator – the highest rating an organization can receive. This rating designates PanCAN as an official “Give with Confidence” charity, indicating strong financial health, ongoing accountability and transparency. Contact Details Patrick van der Valk pvandervalk@xcures.com Company Website https://xcures.com

October 25, 2023 10:15 AM Eastern Daylight Time